Ivonescimab Biosimilar – Anti-VEGF & PD1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1763; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Ivonescimab (AK112) is an antibody developed to target both PD-1 and VEGF pathways, two key mechanisms involved in immune regulation and angiogenesis. It is widely studied in immuno-oncology research for its ability to modulate tumor immune responses while impacting vascular development.
This ivonescimab antibody is used in research to explore combined inhibition of PD-1-mediated immune checkpoint signaling and VEGF-driven angiogenesis. Such dual pathway targeting is of particular interest in studies of tumor progression and therapeutic response.
PD-1 is a key immune checkpoint receptor involved in regulating T-cell activity, while VEGF plays a central role in angiogenesis. Targeting both pathways is widely investigated in oncology research to better understand tumor immune evasion and vascular development.
The price of ivonescimab antibody depends on the required format, quantity, and research specifications. ProteoGenix provides high-quality biosimilars at competitive cost, ensuring accessibility for research applications.
For detailed pricing or bulk orders, you can request a quote directly from our team.
If your research requires specific antibody formats or optimized targeting strategies, custom antibody development solutions can support advanced experimental needs.
ProteoGenix catalogue number PX-TA1763. For research use only.
Target: Ivonescimab Biosimilar – Anti-VEGF & PD1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Ivonescimab Biosimilar – Anti-VEGF & PD1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
